Last reviewed · How we verify

Daclinza and Sunvepra

Pusan National University Hospital · FDA-approved active Small molecule

Daclatasvir and sofosbuvir are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS5B polymerase proteins, respectively, to block viral replication.

Daclatasvir and sofosbuvir are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS5B polymerase proteins, respectively, to block viral replication. Used for Chronic hepatitis C virus infection (genotypes 1-6), Hepatitis C in treatment-naïve and treatment-experienced patients, Hepatitis C with compensated cirrhosis.

At a glance

Generic nameDaclinza and Sunvepra
SponsorPusan National University Hospital
Drug classDirect-acting antiviral (DAA) combination
TargetHCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
ModalitySmall molecule
Therapeutic areaVirology / Hepatology
PhaseFDA-approved

Mechanism of action

Daclatasvir (Daklinza) is an NS5A inhibitor that prevents the formation of the viral replication complex, while sofosbuvir (Sovaldi) is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase. Together, they provide a potent combination therapy that targets two critical steps in the hepatitis C virus lifecycle, achieving high cure rates across multiple genotypes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: